In 2021, the market for Patient-Derived Xenograft Model Market worldwide was worth $170 million US dollars. WMR Group projects that the market will reach US$ 512.4 million by 2031, growing at a CAGR of 13.2 percent between 2022 and 2031.
Industry Overview:
The development of patient-derived xenograft (PDX) models has gained popularity recently with the hope that some systems may be more applicable than mouse and cell line models, and consequently more informative and predictive preclinical treatment models. According to recent studies, customised PDX avatars can predict cancer in patients and even result in specialised cancer treatment. On the other hand, the preservation of each case’s distinct molecular characteristics is necessary for PDX models to perform as actual mouse avatars.
Customised avatar modelling is challenging due to the significant intra-tumor complexity and geographic dispersion of many clones and metastases in many tumour forms. However, there is proof that once created, PDX models are consistent through numerous passes, leading to a reliable, consistent system. The term “patient-derived xenografts” (PDX) refers to cancer models in which humanised or immune-deficient mice are given cells or tissues taken from a patient’s tumour. These simulations of human tumour biology are known to support the development of cancer naturally. This offers a translational research methodology for assessing effectiveness. The manufacture of innovative vaccines and biopharmaceuticals has been made possible by recent advancements in gene expression technology, expanding the research & development uses of patient-derived xenograft model techniques.
Click Here, Download a Free Sample Copy of this Market: https://wemarketresearch.com/sample-request/patient-derived-xenograft-model-market/883/
Market Dynamics
The Patient-Derived Xenograft Model market is expected to grow due to rising cancer cases and increased R&D investment by major market players in the development of new Patient-Derived Xenograft Model products. According to the GLOBOCAN Report 2020, approximately 19,292,789 new cancer cases and 9,958,133 cancer deaths have been reported globally. Breast cancer, lung cancer, colorectum cancer, and prostate cancer are the most common cancers. Similarly, governments in various countries are taking steps to raise consciousness about cancer as well as its diagnosis so that it can be detected earlier. Also in 2022, the Health Minister of Tamil Nadu, State of India, stated that the Tamil Nadu government is working on a policy to identify 66.0% of cancer patients in the first and second stages by 2030, so that proper treatment can be provided. As a result, such a policy is expected to drive market growth. The efficacy of medicines is tested using xenograft animal models.
Prior to clinical development and testing in humans, the mouse model of cancer has continuously been utilized to determine the in vivo activity of new anti-cancer therapeutic applications. As a result, rising cancer cases and initiatives related to cancer diagnosis and treatment are expected to drive market growth over the forecast period. Moreover, the rising price of personalized patient-derived xenograft models as well as stringent regulations regarding the use of animal studies are likely to stymie market growth over the forecast period.
COVID Impact
The COVID-19 pandemic has positively impacted the Patient-Derived Xenograft Model Markets to develop both therapeutic and preventive drugs. Because the pandemic has increased the number of cancer cases and risk factors, more scientific studies are being carried out to study the outcome and investigate new novel treatment technologies. Cancer patients, for example, were more vulnerable to COVID-19, according to a study titled “Effects of cancer on patients with COVID-19, a recent systematic and meta-analysis of 63,019 participants” published in February 2021. Cancer has been associated with a rise in death rates in COVID-19 patients. Among COVID-19 cancer patients, those with lung cancer died at a higher rate than those without lung cancer. According to the study, immunocompromised cancer patients are more prone to serious complications and are more susceptible to COVID-19 than the general population, which can affect the prognosis of the disease.
Regional Trend
Geographically, North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa account for the majority of the global Patient-Derived Xenograft Model market. Because of factors such as rising cancer cases, increased private and public sector investments, and the presence of major players in the region, North America dominates the Patient-Derived Xenograft Model market globally. The Breast Cancer Society of Canada, awarded Precision Oncology Research a USD 350,000 grant in 2022. The selected breast cancer research project will focus on advancements in screening, detection, precision oncology, and patient-reported outcomes, with the goal of improving the care of Canadian women with breast cancer.
Because of the rising incidence of cancer in the region, Asia Pacific is expected to register a higher. The country section of the report also includes individual market impacting factors and changes in market regulation that affect current and future market trends. Downstream and upstream value chain analysis, technical trends and porter’s five forces analysis, and case studies are some of the data points used to forecast the market scenario for individual countries. Additionally, the presence and availability of global brands, as well as the challenges they face due to substantial or scarce competition from domestic and local brands, are taken into account when providing forecast analysis of country data.
Competitive Landscape
Key players operating in the global Patient-Derived Xenograft Model market are Aragen Bioscience, Biocytogen, Bioduro, Champions Oncology, Inc., Charles River Laboratories, Inc., Covance Inc., Creative Animodel, Crown Bioscience, Inc., EPO Berlin-Buch GmbH, Explora BioLabs, GemPharmatech Co., Ltd., Hera BioLabs, Horizon discovery Ltd., Oncodesign, Pharmatest Services Ltd., The Jackson Laboratory, Urolead, Urospehere SAS, Wuxi AppTec, Xenopat and Xentech among others. Recently, GemPharmatech (GemPharmatech Co., Ltd.) announced in July 2022 that it has signed a strategic licence agreement with Charles River Laboratories, Inc. for the exclusive spread of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. Beginning in 2023, Charles River will establish foundation colonies with commercially available models.
Key USP’s-
Professor Kamimura’s research group at Niigata University established a novel pancreatic carcinogenesis model in wild-type rats in April 2022, using the pancreas-targeted sequential hydrodynamic gene delivery method.
Market Segmentation
Based upon the Tumor Type used in Patient-Derived Xenograft Model market is segmented into major segments of Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer and Other Cancer in the Patient-Derived Xenograft Model process. Further it is categorized according to its process and utilization. Based on Model Type, the Patient-Derived Xenograft Model market is segmented into Mice Type and Rats Type. Among the Model Type segments, mice model type segment accounted for the maximum revenue share of 70.4% in 2021 of the Patient-Derived Xenograft Model market. The major factors contributing to the large market share of this segment as the mouse is the foremost mammalian model for examining human illness and health. The mice have a quick reproductive cycle and a long lifespan (one mouse year is equivalent to approximately 30 human years), which keeps the cost, time, and space required for the study manageable.
The Patient-Derived Xenograft Model market is further segmented into Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, as well as CROs & CDMOs. CROs and CDMOs had the highest revenue share of 43.5% and is expected to grow the fastest during the forecast period. Factors driving this segment’s large market share include high mergers and acquisitions, service expansion, and pharmaceutical and biopharmaceutical companies outsourcing their research activities, all of which will contribute to the segment’s growth.
By Tumor Type
• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer
By Model Type
• Mice Type
• Rats Type
By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CDMOs
Get A Report Copy of this Market: https://wemarketresearch.com/reports/patient-derived-xenograft-model-market/883/
Key Questions Answered in the Report:
- What will be the development pace of market? What is the growth rate of the global market?
- Who are the key manufacturers in the market space? Who are the world’s leading manufacturers?
- What are sales, revenue, and price analysis of the top manufacturers of market?
- Who are the distributors, traders, and dealers of market? What are the key factors driving the Global market?
- What are the market opportunities and threats faced by the vendors in the industries?
- What are deals, incomes, and value examinations by types and applications of the market?
- What are the primary factors driving market?
- What are the market’s advantages, disadvantages, and risks, as well as an overview of the market?
- Who are the Top Manufacturers in the Market in Terms of Sales, Revenue, and Price Analysis?
- Analysis of Industry Revenue, Sales, and Pricing, what is the difference between Equipment by region, type, and application?
